Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

ogy treatment through 'personalized medicine'," said Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer. "We now look forward to the presentation of Phase 2 results for AEZS-108 in advanced endometrial cancer at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics." Third Quarter 2010 Highlights (All amounts are in U.S. dollars)

  • Perifosine received orphan-drug designation by the United States Food and Drug Administration ("FDA") for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants (July 14, 2010).
  • Dr. Jacek Pinski of the Norris Comprehensive Cancer Center awarded a grant from the National Institutes of Health ("NIH") for a Phase 1/2 study in advanced refractory prostate cancer with AEZS-108 (August 5, 2010).
  • An abstract on SolorelTM, an oral synthetic ghrelin receptor agonist currently in Phase 3 as a diagnostic test for Adult Growth Hormone Deficiency ("AGHD") was presented at the Seventh International Congress of Neuroendocrinology in Rouen, France. The data showed that Solorel's accuracy was at least equivalent to the current tests for AGHD (July 14, 2010).
  • Interim Phase 3 data on Solorel demonstrating the potential to provide a simple, well tolerated and safe oral diagnostic test for AGHD was also presented at the Fifth International Congress of the Growth Hormone Research Society and the Insulin-like Growth Factors Society in New York City (October 5, 2010).
  • "Our financial position continues to be solid with $39.9 million in cash and cash equivalents at quarter-end and a current controlled burn rate of approximately $2 million per month," said Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris. CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2010Revenues were $5.7 million for the three-month period end
    '/>"/>

    SOURCE AETERNA ZENTARIS INC.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
    2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
    3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
    4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
    5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
    6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
    7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
    8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
    9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
    10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
    11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
    (Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
    (Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
    (Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
    Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
    ... PharmAthene, Inc.,(NYSE: PIP ) a biodefense ... announced today that its financial results,for the third ... November 13,2008., PharmAthene management will be hosting ... financial results. The call is scheduled to begin ...
    ... New Facility in Oregon Will Help Ramp Up New Corn Hybrids Faster. ... ... announced plans to construct a parent seed corn production facility in Hermiston, ... Pioneer Hi-Bred is taking to ensure it meets rising demand for ...
    ... researchers are showing that Microsoft SQL ... up to 1 petabyte., REDMOND, Wash., Nov. ... its data management and business,intelligence platform, Microsoft SQL ... software to scale new heights in data warehousing,and ...
    Cached Biology Technology:PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008 2DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain 2DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain 3Could Database Software Help Cure Alzheimer's and Save the Earth? 2Could Database Software Help Cure Alzheimer's and Save the Earth? 3
    (Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
    (Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
    (Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
    Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
    ... QS-21A, a medicinally important molecule that helps the body ... University of Illinois at Urbana-Champaign. , In clinical trials, ... immune response in vaccine therapies against aggressive diseases such ... HIV-1 and malaria. An extract from the bark of ...
    ... have shown that a commonly used procedure to remove ... does not improve patient outcomes. , The procedure, called ... angioplasty in vein grafts and stenting in carotid arteries. ... the Journal of the American Medical Association, found that ...
    ... cells, the immune system's sentinels, patrol the labyrinthine blood ... tissue damage and demonstrate a dogged behavior not seen ... show that NKT cells crawl along vessel walls, even ... receive a chemical signal to unleash an immune-system assault ...
    Cached Biology News:Columbia study shows widely used artery clearing device does not help patients during heart attack 2Natural Killers Could Lead to New Hepatitis Treatments 2Natural Killers Could Lead to New Hepatitis Treatments 3Natural Killers Could Lead to New Hepatitis Treatments 4
    ... yellow solution. In PBS ... and other proprietary stabilizers; ... formulated to stabilize activity ... conjugates at high conjugate ...
    ... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
    ... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
    ... ReadySub-Cell GT cell and PowerPac basic power supply ... nucleic acids in agarose gels. The mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
    Biology Products: